MedTrace Logo

Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma

NCT06429150 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-04-24

No results posted yet for this study

Summary

The aim of this clinical trial is to assess the feasibility, safety, and efficacy of CAR-T cell therapy targeting multiple cancer cell antigens in high-risk multiple myeloma or plasmacytoma as part of a frontline treatment regimen for patients. Another goal of the study is to learn more about the persistence and function of these CAR-T cells in the body.

Conditions

Interventions

BIOLOGICAL

CAR-T cells

Infusion of multi-CAR-T cells

Sponsors & Collaborators

  • The No.2 Clinical Hospital of the Ministry of Health

    collaborator UNKNOWN

  • Shenzhen Geno-Immune Medical Institute

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-11
Primary Completion
2027-07-11
Completion
2027-12-31

Countries

  • China
  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06429150 on ClinicalTrials.gov